新活素联合左西孟旦治疗难治性心衰的临床研究  

Clinical study of treatment of refractory heart failure about Natriuretic peptide and Levosimendan

作　　者：卞静 宋涛[1] 赵严 温琳琼 

机构地区：[1]武警辽宁省总队医院内一科,辽宁沈阳110034

出　　处：《当代医学》2018年第3期50-53,共4页Contemporary Medicine

摘　　要：目的观察新活素联合左西孟旦治疗难治性心衰的临床疗效。方法随机选择顽固性心衰患者100例分为观察组和对照组,各50例,对照组患者在给予心衰的常规治疗基础上给予新活素,观察组在对照组治疗基础上增加左西孟旦,观察两组患者临床疗效,治疗前后生命体征、NT-proBNP、PRA、AngⅡ、ALD水平以及不良反应情况并进行比较。结果治疗7 d后观察组治疗的总有效率为94.00%明显高于对照组78.00%。治疗后3 d、7 d观察组患者HR、R、SP、DP以及24 h尿量改善情况明显优于对照组,但3 d时组间差异明显大于7 d。治疗后3 d、7 d观察组患者NT-proBNP、PRA、AngⅡ、ALD水平改善情况明显优于对照组,但3 d时组间差异明显大于7 d(P<0.05)。两组患者治疗后不良反应无明显差异。结论新活素联合左西孟旦能够明显提高难治性心衰的临床疗效,在较短时间内起到更明显改善患者的生命体征和相关指标的作用,且具有较好的安全性。Objective Observe clinical study of treatment of refractory heart failure about Natriuretic peptide and Levosimendan.Methods Select 100 patients with RHF in random and divided into observation group and control group,each group has 50 examples.The patient of control group accepted Natriuretic peptide om the basis of conventional control group.To observe the clinical effect of two groups of patient,vital signs before and after treatment.The level of NT-proBNP、PRA、AngⅡ、ALD and adverse reactions and make comparisons.Results The total effective rate of observation group is 94.00% after the treatment of 7 days apparently higher than control group's 78.00%.The HR、R、SP、DPand the improvement of urine volume on 24 hours of the patients in the observation group apparently higher than control group'after the treatment of 3 days、7 days,but the difference between groups after 3 days apparently higher than 7 days.The improvement of NT-proBNP、PRA、AngⅡ、ALD's level apparently higher than control group'.But the difference between two groups after 3 days apparently higher than 7 days(P<0.05).The adverse reaction of two groups has no obvious difference.Conclusion Natriuretic peptide and Levosimendan can obviously improve clinical efficacy of RHF,play a more obviously better role in the patient's vital signs and index of correlation in a relatively short time and have good security.

关 键 词：新活素 左西孟旦 难治性心衰 临床疗效 

分 类 号：R541.6[医药卫生—心血管疾病]